M
Michael A. Bolognese
Researcher at Amgen
Publications - 57
Citations - 9168
Michael A. Bolognese is an academic researcher from Amgen. The author has contributed to research in topics: Osteoporosis & Denosumab. The author has an hindex of 37, co-authored 57 publications receiving 8307 citations. Previous affiliations of Michael A. Bolognese include Merck & Co..
Papers
More filters
Journal ArticleDOI
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung,E. Michael Lewiecki,Stanley B. Cohen,Michael A. Bolognese,Grattan Woodson,Alfred H. Moffett,Munro Peacock,Paul D. Miller,Samuel N. Lederman,Charles H. Chesnut,Douglas Lain,Alan Kivitz,Donna Holloway,Charlie Zhang,Mark C. Peterson,Pirow J. Bekker +15 more
TL;DR: The efficacy and safety of subcutaneously administered denosumab were evaluated in postmenopausal women with low bone mineral density and changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline p...
Journal ArticleDOI
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung,Andreas Grauer,Steven Boonen,Michael A. Bolognese,Jacques P. Brown,Adolfo Diez-Perez,Bente L. Langdahl,Jean-Yves Reginster,Jose R. Zanchetta,Scott M. Wasserman,Leonid Katz,Judy Maddox,Y.-C. Yang,Cesar Libanati,Henry G. Bone +14 more
TL;DR: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption.
Journal ArticleDOI
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom,Tomas Hala,Michael A. Bolognese,Michael J. Lillestol,Phillip D. Toth,Lesley J. Burgess,Richard Ceska,Eli M. Roth,Michael J. Koren,Christie M. Ballantyne,Maria Laura Monsalvo,Kate Tsirtsonis,Jae B. Kim,Robert A. Scott,Scott M. Wasserman,Evan A. Stein +15 more
TL;DR: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high- dose atorVastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks.
Journal ArticleDOI
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
Paul D. Miller,Michael A. Bolognese,E. Michael Lewiecki,Michael R. McClung,Beiying Ding,M. Austin,Yu Liu,Javier San Martin +7 more
TL;DR: In postmenopausal women with low BMD, long-term denosumab treatment led to gains in BMD and reduction of BTM throughout the course of the study, and the effects on bone turnover were fully reversible with discontinuation and restored with subsequent retreatment.
Journal ArticleDOI
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Henry G. Bone,Michael A. Bolognese,Chui Kin Yuen,David L. Kendler,Paul D. Miller,Y.-C. Yang,Luanda Grazette,Javier San Martin,J. Christopher Gallagher +8 more
TL;DR: In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action.